Cite

HARVARD Citation

    Peters, S. et al. (n.d.). 1385PDA randomised phase III trial evaluating the addition of denosumab to standard first-line treatment in advanced NSCLC: The ETOP and EORTC SPLENDOUR trial. Annals of oncology. p. . [Online]. 
  
Back to record